Why the study?
Arrhythmic risk stratification and the role of an implantable cardioverter-defibrillator for primary prevention of sudden cardiac death in cardiac amyloidosis remain unclear.
Does implantable cardioverter-defibrillator (ICD) placement improve survival and prevent sudden cardiac death in patients with cardiac amyloidosis?
Does implantable cardioverter-defibrillator (ICD) placement improve survival and prevent sudden cardiac death in patients with cardiac amyloidosis?
ICD implantation in cardiac amyloidosis remains controversial due to the high risk of death from electromechanical dissociation rather than ventricular arrhythmias, highlighting the need for better arrhythmic risk stratification.
Answers are grounded in this paper and cite their sources.
Unclear ICD role for primary SCD prevention in cardiac amyloidosis persists; leaves open need for prospective risk-stratification trials.
Cardiac amyloidosis (CA) is considered to be associated with an increased risk of sudden cardiac death (SCD) due to ventricular tachyarrhythmias and electromechanical dissociation. However, current arrhythmic risk stratification and the role of an implantable cardioverter-defibrillator (ICD) for primary prevention of SCD remains unclear. This article provides a narrative review of the literature on electrophysiological abnormalities in the context of ventricular arrhythmias in patients with CA and the role of ICD in terms of survival benefit in this group of patients.
No takes yet. Share an insight, caveat, or question.
Liżewska-Springer et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: